JPRN-UMIN000004883已完成2 期
JAPANESE - Skin Toxicity Evaluation Protocol With Panitumumab as 3rd line treatment for Colorectal Cancer(J-STEPP),(HGCSG1001) - J-STEPP(HGCSG1001)
Hokkaido Gastrointestinal Cancer Study Group(HGCSG)0 个研究点目标入组 102 人开始时间: 2011年1月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(a)Patient who have previous history of hypersensitivity in Panitumumab and other medicines (b)The KRAS mutation type. (c)pregnant woman or possibility pregnancy while suckling walking (d)Patient with interstitial pneumonia (e)the anti-EGFR antibody had been administered so far. (f)Patient who is administering bevacizumab (g)Patient who is judged improper by Doctor.
研究者
相似试验
已完成
不适用
To know the safety of Investigational products by assessing the irritation after patch application on healthy human volunteersCTRI/2013/01/003326ITC RD CENTRE24
已完成
不适用
To know the safety of Investigational products by assessing the irritation after patch application onhealthy human volunteersCTRI/2012/12/003246ITC RD CENTRE24
已完成
不适用
To know the safety of Investigational products by assessing the irritation after patch application onhealthy human volunteersCTRI/2013/04/003595ITC RD CENTRE23
已完成
不适用
Evaluation of dermatological safety of investigational products by primary irritation patch test on healthy human volunteers of varied skin typesCTRI/2018/03/012314ITC LIMITED ITC Life Sciences and Technology Centre24
尚未招募
不适用
Primary Irritation Patch Test on Humans with Normal and Sensitive SkiCTRI/2021/03/032138Dabur India Limited